The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness

The effects of the 5 alpha-reductase inhibitor, finasteride, on scalp skin testosterone (T) and dihydrotestosterone (DHT) levels were studied in patients with male pattern baldness. In a double blind study, male patients undergoing hair transplantation were treated with oral finasteride (5 mg/day) o...

Full description

Saved in:
Bibliographic Details
Published inThe journal of clinical endocrinology and metabolism Vol. 79; no. 3; p. 703
Main Authors Dallob, A L, Sadick, N S, Unger, W, Lipert, S, Geissler, L A, Gregoire, S L, Nguyen, H H, Moore, E C, Tanaka, W K
Format Journal Article
LanguageEnglish
Published United States 01.09.1994
Subjects
Online AccessGet more information
ISSN0021-972X
DOI10.1210/jc.79.3.703

Cover

Abstract The effects of the 5 alpha-reductase inhibitor, finasteride, on scalp skin testosterone (T) and dihydrotestosterone (DHT) levels were studied in patients with male pattern baldness. In a double blind study, male patients undergoing hair transplantation were treated with oral finasteride (5 mg/day) or placebo for 28 days. Scalp skin biopsies were obtained before and after treatment for measurement of T and DHT by high pressure liquid chromatography-RIA. In 10 male subjects studied at baseline, mean (+/- SEM) DHT levels were significantly higher in bald (7.37 +/- 1.24 pmol/g) compared to hair-containing (4.20 +/- 0.65 pmol/g) scalp, whereas there was no difference in mean T levels at baseline. In bald scalp from 8 patients treated with finasteride, the mean DHT concentration decreased from 6.40 +/- 1.07 pmol/g at baseline to 3.62 +/- 0.38 pmol/g on day 28. Scalp T levels increased in 6 of 8 subjects treated with finasteride. Finasteride decreased the mean serum DHT concentration from 1.36 +/- 0.18 nmol/L (n = 8) at baseline to 0.46 +/- 0.10 nmol/L on day 28 and had no effect on serum T. There were no significant changes in scalp or serum T or DHT in placebo-treated patients. In this study, male subjects treated with 5 mg/day finasteride for 4 weeks had significantly decreased concentrations of DHT in bald scalp, resulting in a mean level similar to the baseline levels found in hair-containing scalp.
AbstractList The effects of the 5 alpha-reductase inhibitor, finasteride, on scalp skin testosterone (T) and dihydrotestosterone (DHT) levels were studied in patients with male pattern baldness. In a double blind study, male patients undergoing hair transplantation were treated with oral finasteride (5 mg/day) or placebo for 28 days. Scalp skin biopsies were obtained before and after treatment for measurement of T and DHT by high pressure liquid chromatography-RIA. In 10 male subjects studied at baseline, mean (+/- SEM) DHT levels were significantly higher in bald (7.37 +/- 1.24 pmol/g) compared to hair-containing (4.20 +/- 0.65 pmol/g) scalp, whereas there was no difference in mean T levels at baseline. In bald scalp from 8 patients treated with finasteride, the mean DHT concentration decreased from 6.40 +/- 1.07 pmol/g at baseline to 3.62 +/- 0.38 pmol/g on day 28. Scalp T levels increased in 6 of 8 subjects treated with finasteride. Finasteride decreased the mean serum DHT concentration from 1.36 +/- 0.18 nmol/L (n = 8) at baseline to 0.46 +/- 0.10 nmol/L on day 28 and had no effect on serum T. There were no significant changes in scalp or serum T or DHT in placebo-treated patients. In this study, male subjects treated with 5 mg/day finasteride for 4 weeks had significantly decreased concentrations of DHT in bald scalp, resulting in a mean level similar to the baseline levels found in hair-containing scalp.
Author Unger, W
Lipert, S
Nguyen, H H
Dallob, A L
Geissler, L A
Moore, E C
Sadick, N S
Tanaka, W K
Gregoire, S L
Author_xml – sequence: 1
  givenname: A L
  surname: Dallob
  fullname: Dallob, A L
  organization: Merck Research Laboratories, Rahway, New Jersey 07065
– sequence: 2
  givenname: N S
  surname: Sadick
  fullname: Sadick, N S
– sequence: 3
  givenname: W
  surname: Unger
  fullname: Unger, W
– sequence: 4
  givenname: S
  surname: Lipert
  fullname: Lipert, S
– sequence: 5
  givenname: L A
  surname: Geissler
  fullname: Geissler, L A
– sequence: 6
  givenname: S L
  surname: Gregoire
  fullname: Gregoire, S L
– sequence: 7
  givenname: H H
  surname: Nguyen
  fullname: Nguyen, H H
– sequence: 8
  givenname: E C
  surname: Moore
  fullname: Moore, E C
– sequence: 9
  givenname: W K
  surname: Tanaka
  fullname: Tanaka, W K
BackLink https://www.ncbi.nlm.nih.gov/pubmed/8077349$$D View this record in MEDLINE/PubMed
BookMark eNpVkE1qwzAQhbVISZO0q64Lc4A4lWTLspYl9A8C3aTQXZCtMVbqSMZSKLlOT1qFZtPVzHwz83i8OZk475CQO0ZXjDP6sG9WUq3ylaT5hMwo5SxTkn9ek3kIe0pZUYh8SqYVlTIv1Iz8bDsEbFtsIvgWWut0iDhag0vQIED3Q6ezEc2xiTogWNfZ2kY_LsE7CE3aQ_iyDiKG6M-vyQ9oZ8DY7mRG_4833jXo4qij9S4kMRhSm0iAbxs7OOgezyidO6h1bxyGcEOuWt0HvL3UBfl4ftquX7PN-8vb-nGTNVzkMRN1WUlVcqGE5BXXOaXKVHlBq5arWpUyTSmiUiHjRaUpT4BRIxWrURkh-ILc_-kOx_qAZjeM9qDH0-6SFf8FNDBtSw
CitedBy_id crossref_primary_10_1016_S0960_0760_96_00099_4
crossref_primary_10_1002_j_1939_4640_1997_tb02434_x
crossref_primary_10_1016_S0960_0760_98_00059_4
crossref_primary_10_1046_j_1365_4362_2000_00068_x
crossref_primary_10_3389_fgene_2021_794476
crossref_primary_10_1016_S0022_5347_05_68270_5
crossref_primary_10_1046_j_1365_4362_1997_00191_x
crossref_primary_10_1111_j_1468_3083_1999_tb01030_x
crossref_primary_10_1016_S1472_6483_10_61100_5
crossref_primary_10_1080_15265161_2011_568586
crossref_primary_10_1034_j_1600_0625_2002_110106_x
crossref_primary_10_1016_j_mce_2012_05_005
crossref_primary_10_1016_j_bmcl_2004_10_017
crossref_primary_10_4236_health_2019_1110101
crossref_primary_10_1016_S1367_5931_97_80017_8
crossref_primary_10_4333_KPS_2006_36_2_143
crossref_primary_10_1016_S0960_0760_01_00092_9
crossref_primary_10_1016_S0733_8635_05_70396_X
crossref_primary_10_1016_S0960_894X_98_00339_4
crossref_primary_10_1046_j_1365_2133_2000_03780_x
crossref_primary_10_1016_j_jaad_2010_12_023
crossref_primary_10_1016_0378_4347_95_00323_1
crossref_primary_10_1097_GOX_0000000000000005
crossref_primary_10_1016_S0190_9622_99_70081_2
crossref_primary_10_1046_j_1365_4362_1999_00804_x
crossref_primary_10_1089_jmf_2017_0016
crossref_primary_10_1016_S0190_9622_99_80051_6
crossref_primary_10_1067_mjd_2002_120537
crossref_primary_10_1046_j_1365_4362_1998_00542_x
crossref_primary_10_1016_j_ghir_2011_07_003
crossref_primary_10_1016_j_ijpharm_2006_05_041
crossref_primary_10_1016_S0378_5173_99_00359_2
crossref_primary_10_1111_ics_12764
crossref_primary_10_1111_j_1473_2165_2007_00297_x
crossref_primary_10_1016_S0190_9622_98_70007_6
crossref_primary_10_1016_S0968_0896_02_00254_7
crossref_primary_10_1016_j_jaad_2003_11_073
crossref_primary_10_1089_153082001753231036
crossref_primary_10_1111_j_1527_3458_2006_00053_x
crossref_primary_10_1056_NEJM199909233411307
crossref_primary_10_1016_j_jaad_2008_07_001
crossref_primary_10_1016_j_paid_2007_10_003
crossref_primary_10_1016_S0923_1811_02_00145_7
crossref_primary_10_1016_S0733_8635_05_70017_6
crossref_primary_10_1111_jocd_12051
crossref_primary_10_1016_j_jaad_2009_09_018
crossref_primary_10_1016_S0303_7207_02_00372_6
crossref_primary_10_1016_j_jaad_2005_07_001
crossref_primary_10_1046_j_1440_0960_1999_00323_x
crossref_primary_10_1016_S0090_4295_98_00108_3
crossref_primary_10_1016_S0968_0896_01_00012_8
crossref_primary_10_1016_S0213_9251_01_72461_6
crossref_primary_10_1016_S0026_0495_03_00060_X
crossref_primary_10_1200_JCO_2002_10_018
crossref_primary_10_1016_S0960_894X_97_10156_1
crossref_primary_10_1002_j_1939_4640_1996_tb01828_x
crossref_primary_10_1016_S0039_128X_98_00020_8
crossref_primary_10_1111_ijd_12060
crossref_primary_10_1016_j_jaad_2006_05_007
crossref_primary_10_1016_S0039_128X_97_00048_2
crossref_primary_10_1016_j_sder_2009_01_001
crossref_primary_10_1046_j_1365_4362_2000_00019_x
crossref_primary_10_1111_jdv_15171
crossref_primary_10_1186_1472_6904_6_7
crossref_primary_10_1016_S0190_9622_99_80052_8
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1210/jc.79.3.703
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
ExternalDocumentID 8077349
Genre Clinical Trial
Randomized Controlled Trial
Journal Article
GroupedDBID ---
-~X
.55
.GJ
.XZ
08P
0R~
18M
1TH
29K
2WC
34G
354
39C
3O-
3V.
4.4
48X
53G
5GY
5RS
5YH
7X7
88E
8F7
8FI
8FJ
AABZA
AACZT
AAIMJ
AAJQQ
AAKAS
AAPGJ
AAPQZ
AAPXW
AAQQT
AARHZ
AAUAY
AAUQX
AAVAP
AAWDT
AAWTL
AAYJJ
ABBLC
ABDFA
ABDPE
ABEJV
ABGNP
ABJNI
ABLJU
ABMNT
ABNHQ
ABOCM
ABPMR
ABPPZ
ABPQP
ABPTD
ABQNK
ABUWG
ABVGC
ABWST
ABXVV
ACFRR
ACGFO
ACGFS
ACPRK
ACUTJ
ACYHN
ACZBC
ADBBV
ADGKP
ADGZP
ADHKW
ADQBN
ADRTK
ADVEK
ADZCM
AELWJ
AEMDU
AENEX
AENZO
AERZD
AETBJ
AEWNT
AFCHL
AFFNX
AFFQV
AFFZL
AFGWE
AFKRA
AFOFC
AFRAH
AFXAL
AFYAG
AGINJ
AGKRT
AGMDO
AGQXC
AGUTN
AHMBA
AHMMS
AI.
AJEEA
ALMA_UNASSIGNED_HOLDINGS
APIBT
APJGH
AQDSO
AQKUS
ARIXL
ASPBG
ATGXG
AVWKF
AZFZN
BAWUL
BAYMD
BCRHZ
BENPR
BEYMZ
BPHCQ
BSWAC
BTRTY
BVXVI
C45
CCPQU
CDBKE
CGR
CS3
CUY
CVF
D-I
DAKXR
DIK
E3Z
EBS
ECM
EIF
EIHJH
EJD
EMOBN
ENERS
F5P
FECEO
FEDTE
FHSFR
FLUFQ
FOEOM
FOTVD
FQBLK
FYUFA
GAUVT
GJXCC
GX1
H13
HMCUK
HVGLF
HZ~
H~9
IAO
IHR
INH
ITC
J5H
KBUDW
KOP
KQ8
KSI
KSN
L7B
M1P
M5~
MBLQV
MHKGH
MJL
N4W
N9A
NLBLG
NOMLY
NOYVH
NPM
NVLIB
O9-
OAUYM
OBH
OCB
ODMLO
OFXIZ
OGEVE
OHH
OJZSN
OK1
OPAEJ
OVD
OVIDX
P2P
P6G
PQQKQ
PROAC
PSQYO
REU
ROX
ROZ
TEORI
TJX
TLC
TMA
TR2
TWZ
UKHRP
VH1
VVN
VXZ
W8F
WHG
WOQ
X52
X7M
YBU
YFH
YHG
YOC
YSK
ZGI
ZXP
ZY1
~02
~H1
ID FETCH-LOGICAL-c253t-5b6879625957282a3009d83408f29b9679d812169e1248a0279d10d791be9d552
ISSN 0021-972X
IngestDate Wed Feb 19 01:25:47 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c253t-5b6879625957282a3009d83408f29b9679d812169e1248a0279d10d791be9d552
PMID 8077349
ParticipantIDs pubmed_primary_8077349
PublicationCentury 1900
PublicationDate 1994-09-01
PublicationDateYYYYMMDD 1994-09-01
PublicationDate_xml – month: 09
  year: 1994
  text: 1994-09-01
  day: 01
PublicationDecade 1990
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The journal of clinical endocrinology and metabolism
PublicationTitleAlternate J Clin Endocrinol Metab
PublicationYear 1994
SSID ssj0014453
Score 1.896729
Snippet The effects of the 5 alpha-reductase inhibitor, finasteride, on scalp skin testosterone (T) and dihydrotestosterone (DHT) levels were studied in patients with...
SourceID pubmed
SourceType Index Database
StartPage 703
SubjectTerms 5-alpha Reductase Inhibitors
Adult
Alopecia - drug therapy
Alopecia - metabolism
Dihydrotestosterone - blood
Dihydrotestosterone - metabolism
Double-Blind Method
Finasteride - pharmacology
Finasteride - therapeutic use
Humans
Male
Middle Aged
Scalp - drug effects
Scalp - metabolism
Testosterone - blood
Testosterone - metabolism
Title The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness
URI https://www.ncbi.nlm.nih.gov/pubmed/8077349
Volume 79
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELa2IFAviFfFW3Pglma1eTi2jwiBKqTupV2ptyqOEzWwm6zacKA_p_-H_8SM7TxYCgIu0a69a3nzfWt7JjPfMPY2MgUXlTCh5NqEqeT0lypUmKVapKaQSWmDMY-X2dEq_XTGz2az75Oopa-dnhfXt-aV_A-q2Ia4UpbsPyA7DIoN-BrxxSsijNe_xtgFZNCZr6qbnGQPaqekmwc8sJm04SXJs3a4XQV1c1HrunMmOuJ-hQhtg6svFOxIJWbo623jniiY-uKbIRWHSXtBSY6NV9p1EehOl9UnyW1wu6Em8jIGOl-bpg_w-DzOeCJWMeRllo1pcf1qRkWoTdkhP9e9wqF1pq_XrXaL2eCyPsmNrwW_HL24K3JVDtGDNt6o3vrkpJPRz-EEi1Xv5-jzDqJQCVt8fVi7XSEaz9FkshALq5zw6waBFi5tEMVcqHky3_kUorvdWK7IhRCJ01L9Y-eOVrfv2WN7QlAdkSW5jvwjrTT1kqj-Z_hkUUqhmkxnn93zg-zYOfa8c_qQPfCGCrxzrHvEZmXzmN0_9qEYT9gNQgmOfNBWMCHfIeTAYYd6MFDvENoGLPGAiAdTggEiD7cQD34mHg4GPfGAiAdEPPDEg554T9nq44fT90ehL_gRFjFPupDrTApFFjkXsYzzBA0AI5N0IatYaZUJfIc3LFMlnkplvoixIVoYoSJdKsN5fMDuNDipZwyiopB5kcVoYag0i3VOzoWowt0pWkils-fswN3d861TdTn3t_3F7zpesv2Rlq_Y3QoXkfI1nkg7_cYi_QMXIpDY
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+effect+of+finasteride%2C+a+5+alpha-reductase+inhibitor%2C+on+scalp+skin+testosterone+and+dihydrotestosterone+concentrations+in+patients+with+male+pattern+baldness&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Dallob%2C+A+L&rft.au=Sadick%2C+N+S&rft.au=Unger%2C+W&rft.au=Lipert%2C+S&rft.date=1994-09-01&rft.issn=0021-972X&rft.volume=79&rft.issue=3&rft.spage=703&rft_id=info:doi/10.1210%2Fjc.79.3.703&rft_id=info%3Apmid%2F8077349&rft_id=info%3Apmid%2F8077349&rft.externalDocID=8077349
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon